作为抗癌剂的VEGF-R1/2小分子抑制剂的全面描述
1Department of Clinical Pharmacology, China Medical University, Shenyang, PR China.
Bioorganic chemistry
|November 5, 2025
概括
本综述分析了从2020-2025年开始的新型血管内皮生长因子受体 (VEGFR) 抑制剂. 这些向疗法显示出开发新抗瘤药物的前景.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生化学
背景情况:
- 血管内皮生长因子受体 (VEGFRs) 是调节血管生成的关键氨酸激酶.
- 在瘤进展中,VEGFR信号传递至关重要,使其成为关键的治疗点.
- 向VEGFR是开发新型抗瘤疗法的关键策略.
研究的目的:
- 系统地审查和分类2020年至2025年期间报告的VEGFR抑制剂.
- 分析这些抑制剂的结构特征,结构活性关系 (SAR) 和药理学特征.
- 为合理设计有效的抗癌药物提供见解.
主要方法:
- 对VEGFR抑制剂进行系统的文献审查和分类.
- 结构多样性的分析,包括伊米达,皮里丁,皮里米丁和醇衍生物.
- 结构-活性关系 (SAR) 和药理学数据的评估.
主要成果:
- 根据其核心化学结构识别和分类新的VEGFR抑制剂.
- 详细介绍了各种类型的抑制剂的结构特征和SAR.
- 与抗瘤活性相关的药理学概要.
结论:
- 新型VEGFR抑制剂表现出多样化的结构支架和有前途的抗瘤潜力.
- 了解SAR对于优化抑制剂有效性和选择性至关重要.
- 这一综述有助于制药化学家设计下一代针对VEGFR的癌症疗法.
相关概念视频
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Rous Sarcoma Virus (RSV) and Cancer
6.2K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
6.2K
Mechanism of Angiogenesis
6.6K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.6K


